The trial, published in Cancer Reports, evaluated a biweekly regimen of gemcitabine plus nab-paclitaxel, a two-drug combination widely known by the abbreviation GnP. In its conventional form, GnP is administered on Days 1, 8, and 15 of a 28-day cycle, a schedule validated by the landmark MPACT trial, which demonstrated a survival advantage over gemcitabine alone in patients with metastatic disease. The Osaka team instead delivered both agents on Days 1 and 15 only, at the standard doses of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, reasoning that fewer infusions per cycle might ease the burden on older bodies without sacrificing efficacy. Retrospective studies of biweekly GnP in broader populations had already hinted at feasibility, reporting median overall survival of around 10 months, but prospective data in patients aged 75 and older had been essentially absent.

Seventeen patients with unresectable pancreatic cancer, either locally advanced or metastatic, enrolled between August 2019 and March 2021. Their median age was 77, with a range of 75 to 81 years, and the vast majority, 76.5 percent, had metastatic disease. All were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, indicating they were still fully ambulatory or capable of light activity, along with adequate blood counts, liver function, and kidney function. The researchers also used the Geriatric-8 screening tool, an eight-item questionnaire designed to capture vulnerabilities that standard performance measures miss, and scores ranged widely from 6 to 17, a reminder that chronological age conceals substantial heterogeneity in physical reserve. Notably, 12 of the 17 patients had hypertension, 7 had hyperlipidemia, and 6 had diabetes, reflecting the comorbidity burden typical of this age group.

The trial employed Simon’s two-stage minimax design, a statistical framework that allows early stopping if a regimen appears unacceptably ineffective. With an expected overall response rate of 30 percent and a rejection threshold of 7 percent, the study required 18 evaluable patients. Seven patients were assessed in the first stage, and once at least one tumor response was confirmed, the trial advanced to its second stage. Planned enrollment was 20 patients, but accrual ended at 17 due to an unstable supply of nab-paclitaxel during the study period, a practical setback that the authors acknowledge constrained the final statistical power of the efficacy analysis.

Despite the smaller-than-planned cohort, the efficacy signals were striking. At the March 31, 2023 data cutoff, with a median follow-up of 16.8 months, the confirmed overall response rate reached 47.1 percent, with all eight responders achieving partial responses. The 95 percent confidence interval ranged from 23.0 to 72.2 percent, comfortably exceeding the prespecified expectation of 30 percent. The disease control rate, which combines complete and partial responses with stable disease, stood at 82.4 percent. Median overall survival was 16.8 months and median progression-free survival was 8.3 months, figures that sit squarely within the range reported for standard three-times-per-cycle GnP in pivotal trials, including the GENERATE (JCOG1611) trial in Japanese patients, which reported median overall survival of 17.1 months in a cohort capped at age 75. One- and two-year survival rates were 58.8 and 29.4 percent, respectively.

Safety results, however, temper any temptation toward celebration. Every patient experienced at least one adverse event, and grade 3 or higher events of any cause occurred in 52.9 percent of the cohort, with treatment-related severe events in 29.4 percent. The most common toxicities of any grade included anemia in 88.2 percent, alopecia in 88.2 percent, decreased white blood cell count in 76.5 percent, fatigue in 76.5 percent, and peripheral sensory neuropathy in 64.7 percent. Among treatment-related severe events, neutropenia led at 17.6 percent. Seven patients experienced serious adverse events, two of which were judged related to the study drugs. No treatment-related deaths occurred, and no patient died from any adverse event during the study, an outcome the investigators emphasize as meaningful in such a fragile population.

Treatment delivery also revealed the limits of any fixed schedule in older adults. Although the biweekly design meant fewer planned infusions, 11 of 17 patients, 64.7 percent, still required at least one dose reduction, most often of nab-paclitaxel, whose median relative dose intensity fell to 87.3 percent compared with 100 percent for gemcitabine. Three patients discontinued protocol treatment because of adverse events: two for peripheral sensory neuropathy and one for grade 2 interstitial pneumonia, all of whom recovered and moved on to subsequent therapy. The authors argue that the frequency of dose reduction underscores that individualized dose adjustment remains essential even under a deliberately gentler schedule, and they suggest that clinicians may reasonably consider starting at a reduced dose in patients with greater geriatric vulnerability, though the study cannot define precise criteria for that decision.

An intriguing exploratory finding was that survival was actually shorter in the four patients with locally advanced disease than in the thirteen with metastatic disease, a reversal of the usual prognostic pattern. The investigators attribute this largely to the very small subgroup size, which makes estimates unstable, and to baseline characteristics suggesting that the locally advanced patients tended to have poorer performance status and lower Geriatric-8 scores. Exploratory analyses confirmed that patients with performance status 0 fared better than those with status 1, while the Geriatric-8 stratification was too small to interpret. What was unambiguous, however, was the role of subsequent treatment: 14 of the 17 patients, 82.4 percent, went on to receive further systemic therapy after stopping the study regimen, most commonly the oral fluoropyrimidine S-1 or fluorouracil plus nanoliposomal irinotecan, and previous research has consistently shown that effective second-line therapy extends survival in advanced pancreatic cancer.

Beyond the numbers, the study raises a question that oncologists increasingly regard as central to geriatric care: the concept of time toxicity, the share of a patient’s remaining life consumed by treatment itself. Real-world data suggest that pancreatic cancer patients receiving palliative chemotherapy spend roughly 10 percent of their remaining life on healthcare-related activities. A biweekly schedule involves fewer clinic visits per cycle than the conventional regimen, and while this trial did not measure time toxicity prospectively, the authors argue the potential convenience benefit deserves rigorous comparative evaluation. They are equally candid about the study’s limitations: it was single-center, single-arm, and small, enrolled only Japanese patients, excluded frail patients through strict performance and organ-function criteria, and did not perform comprehensive geriatric assessment. Still, in a disease where evidence for patients over 75 has long been extrapolated from younger cohorts, the trial delivers something genuinely scarce: prospective, age-specific data showing that a thoughtfully modified regimen can achieve response rates and survival figures comparable to those of standard protocols, and that, with careful monitoring, many older adults can tolerate and benefit from active combination chemotherapy rather than being consigned to monotherapy or supportive care alone.

Subject of Research: Biweekly gemcitabine plus nab-paclitaxel as first-line therapy for pancreatic cancer patients aged 75 and older

Article Title: Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Article References: Ikezawa, K., Imai, T., Takada, R., Yamai, T., Fukutake, N., Urabe, M., Kai, Y., Mukai, K., Nakabori, T., & Ohkawa, K. (2026). Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer. Cancer Reports, 9(9), Article e70691. https://doi.org/10.1002/cnr2.70691

Image Credits: AI Generated

DOI: 10.1002/cnr2.70691

Keywords: pancreatic cancer, gemcitabine, nab-paclitaxel, biweekly chemotherapy, elderly patients, Phase II trial, unresectable disease, overall response rate, peripheral neuropathy, geriatric assessment, overall survival, oncology

The new analysis, published in Annals of Hematology by a team led by researchers at the Children’s Hospital of Chongqing Medical University, pooled data from 83 studies covering 542 patients treated with ruxolitinib-based regimens. Because no randomized controlled trials have ever evaluated ruxolitinib in hemophagocytic lymphohistiocytosis, the investigators conducted a systematic review and single-arm meta-analysis, registered prospectively with PROSPERO under identifier CRD42025639580. Their headline finding: the pooled overall response rate was 87.2 percent, with a 95 percent confidence interval of 80.8 to 92.7 percent and moderate statistical heterogeneity. When the authors split the results by disease subtype, a clear divide emerged. Patients with primary, or familial, hemophagocytic lymphohistiocytosis—a genetic disorder of immune regulation—achieved a response rate of 100 percent in the pooled data, compared with 82.4 percent in secondary forms triggered by infections, malignancies, or autoimmune disease, a difference that was statistically significant.

Survival figures told a similar story in the short term. The pooled overall survival rate was 91.6 percent at two months, falling to 81.6 percent at six months and 73.9 percent at one year, reflecting the relentless attrition that characterizes this syndrome even under modern therapy. Again, the primary form showed an advantage: 100 percent survival at two months versus 87.7 percent in secondary disease. The authors emphasize that these estimates remained robust in sensitivity analyses that excluded individual case reports, which are often criticized for publication bias since clinicians tend to publish successes rather than failures. Of the 83 included studies, 27 were single-arm trials or cohort studies while 56 were case reports or series, making the exclusion analysis a critical test of whether the headline numbers were propped up by anecdote. They were not.

To understand why these results matter, it helps to understand what ruxolitinib actually does. The drug is an inhibitor of Janus kinases 1 and 2, enzymes that sit at the receiving end of signaling pathways used by many inflammatory cytokines, including interferon-gamma and interleukins that drive T-cell and macrophage activation. In hemophagocytic lymphohistiocytosis, hyperactivated CD8-positive T cells and macrophages flood the body with these cytokines, causing fever, spleen enlargement, falling blood counts, liver injury, and, in the worst cases, multi-organ failure. By dampening cytokine signaling at the intracellular level, ruxolitinib acts upstream of the cellular destruction, calming the storm rather than simply suppressing the immune system wholesale with cytotoxic chemotherapy. This mechanism is why hematologists began experimenting with it off-label in the most desperate cases—patients failing standard etoposide-based regimens, for instance, or infants with genetic disease awaiting stem cell transplantation.

The distinction between primary and secondary disease is central to the new findings. Primary hemophagocytic lymphohistiocytosis arises from inherited defects in genes governing the cytotoxic machinery of natural killer cells and CD8 T cells, such as perforin pathways, and historically it was almost always fatal in infancy without hematopoietic stem cell transplantation. Secondary, or acquired, forms erupt on top of infections like Epstein-Barr virus, malignancies, or autoimmune conditions, and their biology is more heterogeneous, reflecting diverse underlying triggers. The higher pooled response rate in the primary form may seem counterintuitive at first—genetic disease might be expected to be harder to treat—but it fits with the drug’s mechanism. In primary disease, the cytokine loop is driven by a relatively uniform defect in cytotoxic function, and blocking the downstream signaling amplifiers may interrupt the feedback circuit very effectively. Secondary disease, by contrast, is entangled with the underlying trigger: a lymphoma continues to grow, a viral infection persists, and ruxolitinib alone cannot remove the source of the inflammation. The authors also observed more frequent pancreatic injury and severe hematological toxicity in the primary group, hinting that treatment intensity or disease biology differs between the subtypes in ways that deserve dedicated study.

Safety data from the synthesis add important nuance for clinicians weighing the drug at the bedside. The most frequent adverse events across the pooled population were infections at 9.3 percent, neutropenia at 7.5 percent, and hepatic dysfunction at 7.0 percent. These figures are notable because they are modest for a drug used in critically ill, profoundly immunosuppressed patients, but they are not trivial. Ruxolitinib’s immunosuppressive mechanism raises a theoretical concern about reactivation of latent infections, and cytomegalovirus reactivation in particular has been reported in clinical experience with the drug. The analysis does not settle that question definitively, and the authors are candid that rare disease research carries inherent limitations: no randomized comparisons, heterogeneous dosing and combination regimens, variable definitions of response across studies, and follow-up that is often short in a syndrome where patients may die quickly or be rescued by transplantation.

Those caveats frame the study’s real contribution. By aggregating every available strand of evidence—trials, cohorts, and hundreds of individually reported cases—the analysis provides the first quantitative benchmark for what clinicians can realistically expect from ruxolitinib-based therapy in each subtype. An 87 percent pooled response rate across the spectrum, with survival above 90 percent at two months, is a signal strong enough to inform practice today and to shape the design of the trials that must follow. The subgroup difference is arguably the most actionable finding: it suggests that in secondary hemophagocytic lymphohistiocytosis, ruxolitinib should probably be positioned as part of a strategy that simultaneously attacks the underlying trigger, whether that is antiviral therapy, chemotherapy for lymphoma, or immunosuppression for autoimmune disease, rather than as monotherapy expected to carry the patient alone.

The authors, led by Zirui Ding with senior authorship from Xi Yang, Xiaodong Zhao, and Ximing Xu among a team spanning Chongqing and Tokyo, including Hirokazu Kanegane of Institute of Science Tokyo, write that their findings provide critical guidance for clinical practice and future trial design despite the limitations inherent in studying a rare disease. The research was supported by grants from Chongqing municipal health and science funding programs, and the work reflects the growing capacity of pediatric immunology and hematology centers in China to mount large evidence syntheses in ultra-rare conditions where no single institution sees enough patients to study them alone.

For the rare disease community, the study lands at a moment of genuine momentum. Ruxolitinib has already been tested in randomized trials for graft-versus-host disease and is approved for several myeloproliferative neoplasms, giving physicians extensive familiarity with its dosing and toxicity profile. The new meta-analysis extends that familiarity into one of hematology’s most lethal emergencies, and its subtype-specific numbers give trial designers a clear benchmark against which future randomized studies of ruxolitinib in primary and secondary disease can be powered. What remains to be shown is whether the dramatic early responses translate into durable cures, particularly for patients with genetic disease who ultimately need stem cell transplantation, and whether the drug’s benefit in secondary forms depends critically on how aggressively the underlying trigger is treated alongside it. Those answers will require the very trials this synthesis is designed to enable.

Subject of Research: Efficacy and safety of the JAK1/JAK2 inhibitor ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis

Article Title: Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis

Article References: Ding, Z., Zhang, Z., Dou, Y., Jia, Y., An, Y., Tang, X., Kanegane, H., Xu, X., Zhao, X., & Yang, X. (2026). Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07274-9

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07274-9

Keywords: hemophagocytic lymphohistiocytosis, ruxolitinib, JAK1/JAK2 inhibitor, meta-analysis, primary HLH, secondary HLH, overall response rate, overall survival, adverse events, rare disease, immunotherapy, hematology